嵌合抗原受体修饰T细胞:CD19及未来之路
本文综述了嵌合抗原受体(CAR)T细胞疗法在血液恶性肿瘤中的现状、挑战与未来应用。靶向CD19的CAR T细胞在难治性B细胞恶性肿瘤中显示出显著抗肿瘤活性,当前研究聚焦于理解肿瘤未完全清除机制、降低毒性、防止抗原逃逸,并基于合成生物学原则确定合适靶点与策略以拓展至其他血液恶性肿瘤。
要点
- 靶向CD19的CAR T细胞在难治性B细胞恶性肿瘤中显示出显著抗肿瘤活性。
- 当前研究聚焦于理解肿瘤未完全清除机制、降低毒性、防止抗原逃逸。
- 基于合成生物学原则确定合适靶点与策略以拓展至其他血液恶性肿瘤。
核心结论
- 靶向CD19的CAR T细胞在难治性B细胞恶性肿瘤中显示出显著抗肿瘤活性,当前研究聚焦于理解肿瘤未完全清除机制、降低毒性、防止抗原逃逸,并基于合成生物学原则确定合适靶点与策略以拓展至其他血液恶性肿瘤。
研究设计与样本
- 综述,讨论CAR T细胞疗法在血液恶性肿瘤中的当前 status、挑战与潜在未来应用。
主要发现
- 过继转移经肿瘤反应性筛选或经天然或合成受体工程化的T细胞已成为有效手段,甚至对常规治疗难治的肿瘤患者亦然。
- 表达合成嵌合抗原受体(CAR)的T细胞可重编程其特异性以靶向CD19,为过继细胞疗法最显著示例。
- 靶向CD19的CAR T细胞在难治性B细胞恶性肿瘤患者中显示出显著抗肿瘤活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ability to harness a patient's immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients with tumors that are refractory to conventional therapies. The most notable example of adoptive cell therapy is with T cells engineered to express synthetic chimeric antigen receptors (CARs) that reprogram their specificity to target CD19. CAR T cells have shown remarkable antitumor activity in patients with refractory B-cell malignancies. Ongoing research is focused on understanding the mechanisms of incomplete tumor elimination, reducing toxicities, preventing antigen escape, and identifying suitable targets and strategies based on established and emerging principles of synthetic biology for extending this approach to other hematologic malignancies. This review will discuss the current status, challenges, and potential future applications of CAR T-cell therapy in hematologic malignancies.
引用
- Salter AI, Pont MJ, Riddell SR, et al. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018. PMID: 29728402. doi:10.1182/blood-2018-01-785840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。